July 17th 2015: Proton Partners International Ltd has been chosen to provide the United Arab Emirates with its first Proton Beam Therapy centre.

Proving that they are not only leading the way for Proton Beam Therapy in the UK but also abroad, Proton Partners has been selected to develop and operate the Abu Dhabi Proton Centre (ADPC) in Abu Dhabi with SBK Holding LLC and Albans Partners General Trading LLC.

Read more

Mike Moran MBE, CEO of Proton Partners International Ltd, said: “I am delighted to be invited to the UAE to support the development of the Abu Dhabi Proton Centre (ADPC).

“Proton Partners International is the United Kingdom’s leading developer of Proton Beam Therapy facilities having recently announced the development of three centres across the UK. We work with world leading technology partners such as Philips, IBA, ORCA and MEI Healthcare and I am thrilled that they will also support us in the development of the ADPC.

“By bringing Proton Beam Therapy to the people of UAE, His Highness Dr. Sheikh Sultan Bin Khalifa Al Nahyan has shown a vision for the future of healthcare in the country and I very much look forward to supporting his aim of delivering the most advanced cancer treatments to the people of the UAE.”

Professor Karol Sikora, Chief Medical Officer of Proton Partners International, said: “It is fantastic that His Highness’ foresight will lead to the first installation of sophisticated proton delivery technology in the Middle East. I am confident that by creating a global network of proton centres connecting leading institutes in Britain with Abu Dhabi is the best way forward.

“Proton therapy is suitable for around 10% of patients receiving conventional radiotherapy and delivers a much more precise dose distribution, sparing normal tissue and so serious long term toxicity. We are confident that with the skills and enthusiasm we’ve seen in Abu Dhabi, we can deliver this project within the next two years.  Cancer incidence is rising dramatically globally and more innovation is needed to deal with this disease. We envisage this development will put the UAE in the frontline of cancer treatment and research.”

Gordon Baltzer, Chairman of the MEI Healthcare Group, said: “Our organisation is truly excited about this opportunity to bring innovative healthcare technology and expertise to patients in the United Arab Emirates.

“The creation of this comprehensive cancer center including innovative proton therapy capability, will ensure access to world class oncology services in the UAE.”

David Knott, Chief Executive Officer for the MEI Healthcare Group, added:  “This innovative and proven team of healthcare partners possess the required expertise and capability to ensure the successful development, construction, and operation of this state-of-the-art oncology program.”

SBK Holding LLC is the Holding Company of His Highness Dr. Sheikh Sultan Bin Khalifa Bin Zayed Al Nahyan, Advisor to the President of the United Arab Emirates, the eldest son of His Highness Sheikh Khalifa Bin Zayed Al Nahyan, President of the United Arab Emirates, Supreme Commander of the UAE Armed Forces, and Ruler of Abu Dhabi.

SBK Holding has a range of companies that serve a broad cross-section of industries not only in the Gulf region but also globally. SBK Holding employs 10,000 employees in the UAE and with its substantial international investments the company has a workforce that reaches all corners of the world.


Further information:
Sophie Watson / Gary McQueen
Media House International Ltd.
0207 710 0020 / 0141 220 6040

About Proton Therapy
Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life. Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 19 additional centers under development.

While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.

About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, has been appointed chairman, Professor Karol Sikora is Chief Medical Advisor and, one of the Founders, Mike Moran MBE has been appointed as the Chief Executive Officer.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems.  In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets.  IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

About Philips
Royal Philips is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries.

The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About MEI Healthcare Group
MEI Healthcare Group is a U.S. based healthcare strategy and development company that provides vertically integrated solutions to the global healthcare community. MEI has more than 40 years of experience in the turn-key planning, development, financing and commercialization of healthcare strategies across a variety of service lines.   MEI’s service portfolio includes project development, equipment selection, financial modelling, advisory and consultative services, and facility management services.  MEI Healthcare Group is led by Gordon Baltzer, Chairman and David Knott, Chief Executive Officer.

Share via Twitter

Share via LinkedIn